Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

By afschroeder • March 31, 2026

Kileel EM, Malvestutto CD, Zanni MV, Davies-Smith E, Fichtenbaum CJ, Lake JE, Lo J, Aberg JA, Martinez E, Patel K, Bloomfield GS, Chu SM, Awwad A, Diggs MR, Lu AB, Bares SH, Berrner D, Smieja M, Okeke NL, Kumar P, João E, Currier JS, Lu MT, Fox MP, Brennan AT, Douglas PS, Grinspoon SK, Ribaudo HJ. Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE. Lancet HIV. 2026 Mar 27:S2352-3018(25)00354-6. doi: 10.1016/S2352-3018(25)00354-6. Epub ahead of print. PMID: 41911941.

Tags: Infectious Diseases, Publications

Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

GBD 2023 Meningitis & Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the[...]

Discovery and cryoEM structure of FPM13, a periplasmic metalloprotein unique to Francisella

Clemens DL, Lee BY, Liu X, Zhou ZH, Horwitz MA. Discovery and cryoEM structure of FPM13, a periplasmic metalloprotein unique to Francisella. PLoS Pathog. 2026[...]

Molecular Characterization of Complete Simian Foamy Virus Genomes from Three Colobine Monkeys Reveals Highly Divergent Evolutionary Trajectories and Identifies Transmission to Humans

Shankar A, Zheng H, Cowan D, Jia H, Osis G, Burgin A, Sheth M, Hoff NA, Halbrook M, Rimoin AW, Goldberg TL, Chapman CA, Ting[...]